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With the recent advances in human-hemato-lymphoid-system mice, this commentary discusses the
utility of these mice and further improvements required to generate an accessible system that allows
predictive in vivo human hematology and immunology research.Knowledge on human physiology and
pathology, for good reasons, is pre-
dominantly gained by observation,
cautious, safety-oriented in vivo ex-
perimentation, and in vitro surrogate
assays. Thus, progress in clinical re-
search is mostly slow, and rigorous
scientific proof is often impossible.
Given appropriate ethical consid-
eration, most societies agree on re-
search involving worms, flies, and
small vertebrates. Because of easy
assess and experimental feasibility,
laboratory mice have become the
main model for in vivo basic and ap-
plied biomedical science. However,
approximately 65 million years of di-
vergence in human and mouse evolu-
tion have shaped these two species
that differ substantially in size, life-
span, reproductive activity, and expo-
sure to environmental challenges, e.g.,
species-specific infectious agents
that coevolved. Thus, with regards to
hematology and immunology, mice
are not men, and this is one of the
reasons that achievements in mice
are often lost in translation (Mestas
and Hughes, 2004).
Increasing use of clinical hemato-
poietic-cell transplantation in malig-
nant disease and immunodeficiencies,
as well as the rise of the devastating
HIV pandemic, led to the need of pre-
dictive testing assays, and thus exper-
imentation with human-hemato-
lymphoid system mice took off almost
20 years ago, resulting in major model
improvements over the last few years.
The detailed history and state of the
art in this field has been reviewed
(Legrand et al., 2006b; Macchiariniet al., 2005; Shultz et al., 2007). This
commentary focuses on the current
status and the necessary progress
to be made in order to meet future
expectations.
Development of Human-Hemato-
Lymphoid-System-Permissive
Mice
For hematopoietic-cell engraftment,
differentiation, and function, some ba-
sic requirements need to be met: Cells
need to locate appropriately, must not
be rejected, andmust be supported by
the host environment. For xenogeneic
transplantation, this requires immune
deficiency of the recipient as well as
species cross reactivity of homing
molecules and differentiation and sur-
vival factors, if not provided by trans-
planted cells themselves.
Mice with a mutation in the Prkdc
gene, causing severe combined T
and B cell immunodeficiency (SCID),
led the way to human to mouse hem-
ato-lymphoid cell and tissue trans-
plantation. In pioneering work, Mosier
et al. transferred human peripheral
blood leukocytes (hu-PBL-SCID
mice) (Mosier et al., 1988); McCune
et al. transplanted human fetal liver he-
matopoietic cells, bone, thymus, and
lymph nodes (SCID-hu mice) (McCune
et al., 1988); and Dick and coworkers
engrafted mice with human bone-
marrow cells (Lapidot et al., 1992).
Both hu-PBL-SCID and SCID-hu
mice are used for studying some
aspects of hemato-lymphopoiesis
and adaptive immune responses;
however, several issues limited their
broad use: hu-PBL-SCID mice pro-Immuniduce recall, but rarely produce, if any,
primary immune responses, and trans-
planted human T cells are activated in
the xenogeneic environment; SCID-hu
mice require multiple human fetal
tissues and are thus labor and cost
intensive, and again, primary immune
responses were rarely detected
(Legrand et al., 2006b; Macchiarini
et al., 2005; Shultz et al., 2007).
A crucial step forward was achieved
by crossing nonobese diabetic (NOD)
and SCID strains in 1995: These
NOD-SCID mice display additional
defects in innate immunity as NK cell,
macrophage, and complement defi-
ciencies, leading to 5- to 10-fold
greater human chimerism upon hema-
topoietic stem cell (HSC) and progeni-
tor-cell transplantation compared to
SCIDmice (Shultz et al., 2007). Conse-
quently, NOD-SCID mice became the
gold standard in vivo model for human
hematopoietic readout. However, be-
cause of lack of human T and B cell
maturation, NOD-SCID mice did not
satisfy the need for immunology re-
search. Furthermore, most NOD-
SCID mice develop lethal thymomas,
limiting long-term follow up (Shultz
et al., 2007).
Proof that cytokine-receptor target-
ing and further NK-cell depletion in
NOD-SCID mice permit even higher
engraftment rates and human T cell
development in the mouse thymus
came from addition of IL-2Rb anti-
bodies to pretransplantation condi-
tioning (Kerre et al., 2002). Concurring
with this work, the most recent im-
provement was achieved with the use
of two new NOD-SCID mouse strainsty 26, May 2007 ª2007 Elsevier Inc. 537
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CommentaryFigure 1. Lymphoid-Tissue Similarities in Human-Hemato-Lymphoid-System Mice
and Men
The upper panel shows spleen sections of a newborn intrahepatic CD34+-cord-blood-cell-
transplanted Rag2/Il2rg/ mouse. The lower panel shows control stains on human tonsils for
comparison.deficient for the common cytokine-
receptor g-chain (Il2rg/, common
to the IL-2, IL-4, IL-7, IL-9, IL-15, and
IL-21 receptors) (Ishikawa et al.,
2005; Ito et al., 2002; Shultz et al.,
2005) and BALB/c, but not C57BL/6,
Rag2/Il2rg/ mice (Gimeno et al.,
2004; Traggiai et al., 2004). All strains
lack mouse T, B, and NK cells have
no obviously high rate of tumor devel-
opment and show normal life spans.
Engraftment and differentiation of hu-
man HSC and progenitor cells are
most efficient, when transplants are
injected into newborn mice, i.e., in
a setting where the recipient organism
is naturally set for maximal hemato-
lymphoid-system expansion, a situa-
tion reminiscent of hematopoietic-cell
transplantation in human infants. Hu-
man CD34+ HSC and progenitor-cell
transplantation into sublethally irradi-
ated newborn NOD-SCID Il2rg/ or
BALB/c Rag2/Il2rg/ mice leads
to differentiation and more than half-
year maintenance of all major cell
populations of the human hemato-
lymphoid system, including dendritic
cells, natural-interferon-producing cells,
T cells, B and immunoglobulin-pro-
ducing cells, and, to somewhat lesser
extent, NK cells, myelo-monocytic
cells, platelets, and erythropoiesis,
as well as formation and structuring
of major hemato-lymphoid organs
(Gimeno et al., 2004; Ishikawa et al.,
2005; Traggiai et al., 2004). An exam-538 Immunity 26, May 2007 ª2007 Elseviple illustrating similarities of lymphoid-
tissue structures in humans and new-
born CD34+-cord-blood-cell-trans-
planted Rag2/Il2rg/mice is shown
in Figure 1.
Human-Hemato-Lymphoid-Cell
Engraftment, Differentiation,
and Function in Permissive Mice
Because up to now in vitro assays do
not allow measurement of HSC
maintenance or expansion, laboratory
animals have been essential in HSC re-
search. Single syngeneicmouse HSCs
are able to generate greater than 50%
hematopoietic chimerism for at least
10 months, and 100 syngeneic-HSC-
enriched cells are capable of rescuing
from hematopoietic lethal irradiation
and of re-establishing HSC homeosta-
sis, whereas at least ten times greater
numbers are needed for radioprotec-
tion of fully MHC-mismatched recipi-
ents. HSC transplantation is currently
the only clinical broadly used, long-
term proven stem cell therapy. In four
to six HLA-antigen-matched, unre-
lated human-cord-blood-cell trans-
plantation, a minimum threshold
number of 1.7 3 105 CD34+ HSC and
progenitor cells/kg recipient weight
has been suggested, and graft durabil-
ity has been demonstrated for over 15
years (Grewal et al., 2003). In contrast,
cell doses needed for robust (>10%)
human to mouse xenogeneic engraft-
ment are in a range of 5 to 50 3 106er Inc.CD34+ cells/kg recipient body weight
(i.e., more than 10- to 100-fold
greater); homeostatic expansion is
not observed, and, although serial
transplantation is possible, the fre-
quency of SCID-repopulating cells
(SRCs) and chimerism declines over
time. Thus, human HSCs seem not to
be maintained or expanded in cur-
rently used mice. Although some of
this might be because of intrinsic dif-
ferences in mouse versus human
HSCs (e.g., different cycling times
[McKenzie et al., 2006]), it is most likely
to also reflect insufficient homing and
cross reactivity of extrinsic, HSC-
nurturing factors in respective niches.
Thus, additional provision of human
components might be beneficial.
Table 1 depicts cross reactivities of
some hemato-lymphopoiesis support-
ing cytokines; it should be noted,
though, that cross reactivity does not
equal biologic activity. Furthermore,
faithful expression will be critical be-
cause overexpression or injection of,
for example, cytokines will not provide
appropriate stimulation for steady-
state hemato-lymphopoiesis. For human
HSC maintenance, addition of human
thrombopoietin and cotransplantation
of human mesenchymal stroma cells
to rebuild a human bone-marrow
microenvironment might be useful
(Muguruma et al., 2006) (Table 2).
Although in vitro myeloid differen-
tiation is readily achieved in colony-
forming assays, human myeloid and
erythro-thrombocytic readout is weak
in currently used mice (Ishikawa
et al., 2005; Legrand et al., 2006b;
Shultz et al., 2007). As discussed
above, in mice, few syngeneic HSCs
are able to radioprotect recipients; ra-
dioprotection is a process dependent
on erythro-megakaryocyte differentia-
tion. In contrast, hematopoietic-cell
transplantation in lethally conditioned
humans regularly requires transient
erythrocyte and thrombocyte transfu-
sions, in part reflecting longer cellular
differentiation times. In my laboratory,
we did not observe radioprotection
upon lethal irradiation of mice with
high doses of human hematopoietic
cells, nor were we able to detect ro-
bust numbers of human erythrocytes
in mouse blood by using blood-group-
testing systems (unpublished data).
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ences in cell size, differentiation, and
survival dynamics, insufficient human
myelo-erythro-megakaryocyte differ-
entiation in mice possibly also results
from inappropriate cytokine cross re-
activity. Furthermore, because recipi-
ent mice have grossly intact myeloid
cellular compartments, there is no de-
ficiency to be compensated, and hu-
man cells are likely to be outcompeted
by mouse cells in recovery of irradia-
tion-induced cytopenia. Thus, it is rea-
sonable to expect that nonlethal
genetic deletion of insufficient cross-
reactive mouse myeloid growth fac-
Table 1. Cross-Species Reactivity
of Some Hemato-Lymphoid
Development Relevant Cytokines
Human
Active
on Mouse
Mouse
Active
on Human
Flt3-Ligand + +
SCF  +
EPO + 
TPO + +
G-CSF + +
M-CSF + 
GM-CSF  
IL-2 + 
IL-3  
IL-6 + 
IL-7 + +
IL-15 + +
Cross-reactivity does not equal biologic
activity.tors, and replacement by respective
human ones that ideally would not
stimulate mouse receptors, will lead
to improved human cell differentiation.
In addition, transient deletion ofmouse
myeloid cells might be a reasonable
approach.
In reconstituted mice, human NK
cells are detected at low frequencies,
but in vivo, functional properties have
not been studied. Functional human
dendritic cells (DCs) and natural type
I interferon-producing cells (IPCs or
plasmacytoid dendritic cells) are
present in the bone marrow, spleen,
lymph nodes, thymus, and liver, and
Langerhans-cell differentiation was
observed at least in one report
(Palucka et al., 2003; Traggiai et al.,
2004). Thus, in vivo antigen processing
and presentation on human MHC
should be possible.
The major improvement achieved
by transplanting human HSC and pro-
genitor cells in newborn NOD-SCID
Il2rg/ and Rag2/Il2rg/ recipi-
ents is efficient intrathymic de novo
human T cell development (Gimeno
et al., 2004; Ishikawa et al., 2005;
Traggiai et al., 2004), a process reca-
pitulated weakly in adult transplanted
NOD-SCID Il2rg/ recipients upon
addition of human IL-7 (Shultz et al.,
2005). Thymic-generated cells include
CD4+ and CD8+ T cells with a broad Vb
distribution, Foxp3+ CD25+ regulatory
T cells, and gd T cells in fairly physio-
logic ratios. Upon maturation, T cells
exit the thymus and seed secondary
lymphoid organs. Isolated from these
sites, the generated T cells are capa-
ble of proliferating and producingImmuncytokines upon unspecific stimulation.
What MHC restriction is to be ex-
pected from human T cells educated
on a mouse background? Mostly
mouse-generated data demonstrate
that under normal developmental
conditions, positive selection prefer-
entially occurs on epithelial cells,
whereas both epithelial cells and he-
matopoietic-derived DCs are involved
in negative selection. As predicted by
embryonic germ-layer derivation, we
did not observe human thymic epithe-
lial cells in CD34+-cell-transplanted
mice, whereas bothmouse and human
cells constitute the thymic DC com-
partment (Traggiai et al., 2004). Human
thymocytes should thus be positively
selected on mouse, whereas negative
selection could occur on both mouse
and human MHC. However, it is rea-
sonable to expect that thymocytes
would continue to interact with mouse
MHC during successive selection.
Complicating the issue, several stud-
ies onmice point out that under certain
conditions, hematopoietic offspring
cells are involved in positive selection
(e.g., Zinkernagel and Althage [1999]);
moreover, species-specific differ-
ences might exist, allowing human
thymocyte-thymocyte MHC class II
interaction, and thus at least some
CD4+ T cell selection might occur on
human MHC (e.g., Choi et al. [2005]).
Once T cells exit the thymus, they
depend on homeostatic factors, both
MHC, and cytokines for survival. For
the mice discussed here, human
MHC is only present on hematopoietic
but no other tissues. Presentation of
both ‘‘self’’ and ‘‘nonself’’ antigensTable 2. Human-Hemato-Lymphoid-System Mice: Limitations and Some Potential Solutions
Limitations Possible Solutions
Human hematopoietic stem cell maintenance Faithful expression of human cytokines (e.g., thrombopoietin);
creation of humanized stem cell niche (e.g., human mesenchymal
stem cell co-transplantation)
Human myeloid-cell differentiation Deletion of nonlethal, weak or not cross-reactive mouse cytokines;
faithful expression of preferentially weak or nonmouse cross-reactive
human counterpart cytokines (e.g., GM-CSF, IL-3); deletion of mouse
myeloid cell components (transient pharmacologic or genetic deletion)
Human T and B cell selection and maintenance Deletion of mouse MHC class I and II; expression of human MHC
class I and II (preferentially haplotypes)
Lymphoid-organ formation and structuring Deletion of mouse IL-2Rb-chain instead of common g-chain
Standardized human cell transplants Generation of human HSCs from embryonic stem cells or multipotent
adult progenitor cells; in vitro expansion of HSCsity 26, May 2007 ª2007 Elsevier Inc. 539
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well as the efficacy of cells to take up
extracellular antigens and present
these in context of both MHC class I
and II.
So what human T cell responses are
observed in this complicated situa-
tion? First, in mixed lymphocyte reac-
tions (MLRs), human T cells proliferate
vigorously when stimulated with hu-
man allogeneic DCs but proliferate
weakly or not at all when stimulated
with human autologous DCs. Prolifera-
tive response to mouse DCs is overall
low; however, T cell proliferation is
stronger when stimulated with fully
mismatched than with host-mouse-
type DCs (Traggiai et al., 2004). Sec-
ond, human T cells generated in mice
display activity against human alloge-
neic target cells that could be blocked
with human MHC class I or II anti-
bodies, respectively (Ishikawa et al.,
2005). Third, human T cells in mice
mount some responses to in vivo
infection with Epstein-Barr virus, mim-
icking to some extent infectiousmono-
nucleosis. Frequently, however, they
were not capable of controlling EBV-
driven B cell proliferation (Traggiai
et al., 2004). Interestingly, by further
testing of HLA-A2 and HLA-B8 cord
blood CD34+-cell-transplanted mice,
tetramer-staining positive CD8+ T cells
were not detected with most com-
monly recognized EBV specific epi-
topes (unpublished data), whereas in
acutely infected human beings, often
up to half of CD8+ T cells show EBV
specificity. Fourth, upon mouse infec-
tion with influenza virus, human T cells
specific for viral epitopes are only ob-
served in the context of mouse MHC
(Legrand et al., 2006b); and, although
based on limited data, robust specific
T cell responses in HIV-infected mice
have not been demonstrated so far
(e.g., Baenziger et al. [2006]). Last, no
relevant homeostatic cell expansion
was observed when mouse-derived
human T cells were transferred to non-
transplanted Rag2/Il2rg/ mice.
Along the same lines, others observed
high peripheral T cell turnover rates
and lack of long-term T cell mainte-
nance (Legrand et al., 2006b).
In summary, current data allow no
firm conclusion on the biology of T
cell selection in this setting but sug-540 Immunity 26, May 2007 ª2007 Elsevgest T cell tolerance, i.e., possibly neg-
ative selection, for both autologous
human and mouse MHC. Reactions,
at least against human allogeneic
MHC, seem to be frequent, and rare
specific responses in the context of
autologous human and mouse MHC
might be produced. These consider-
ations do not account for insufficient
cross-species costimulation and,
overall, stir some concern that any
human T cell response observed in
described settings might be the result
of an ‘‘in vivo artifact.’’ Although this
might be an opportunity to study
some aspects of T cell biology, the ob-
vious appropriate and urgently needed
solution for generating robust human T
cell responses and maintenance is re-
placement of mouse by human MHC
components (Table 2); this replace-
ment creates, at least for thymic selec-
tion, a similar situation as in mice
cotransplanted with same human do-
nor fetal thymic tissue. Along this
way, it will be interesting to evaluate
human T cell development in the
absence of tissue MHC, a situation
mimicking allogeneic hematopoietic-
cell transplantation in human MHC
deficiencies.
Further indicating the impact of en-
vironment, the relative distribution of
human cells reflects values observed
in mice rather than in human blood. In-
deed, B cells generated in the bone
marrow and seeding secondary lym-
phoid organs are the major human
cell population in transplanted animals
(Legrand et al., 2006b; Macchiarini
et al., 2005; Shultz et al., 2007). Matu-
ration to human antibody-producing
cells including class-switch recombi-
nation was only observed in mice
with human T cell development,
suggesting provision of some help.
Human IgG concentrations increase
over time and are on average approxi-
mately two logs and one log lower than
in human adults and wild-type labora-
tory mice, respectively (Baenziger
et al., 2006; Traggiai et al., 2004).
Specific IgG antibody responses to
T cell-dependant antigens such as
tetanus toxoid, ovalbumin, and HIV
epitopes are observed. However,
absolute concentrations are low, and
responses lacked consistency (Baen-
ziger et al., 2006; Ishikawa et al.,ier Inc.2005; Traggiai et al., 2004), possibly
in part because of inadequate T cell
help. Although human cells (probably
lymphotoxin-a-expressing B cells) in-
duce formation of mouse follicular
dendritic cells (FDCs), lack of human
FDCs is likely to further impinge on B
cell responses (Traggiai et al., 2004).
Thus, providing adequate human
MHC as well as supporting B cell mat-
uration by addition of human stroma
cells with FDC differentiation capacity
(Munoz-Fernandez et al., 2006) should
lead to improved humoral responses
(Table 2).
Upon human CD34+-cell transplan-
tation to newborn NOD-SCID Il2rg/
and Rag2/Il2rg/ recipients, newly
formed human cells seed the thymus,
spleen, and mesenteric lymph nodes,
thus leading to an increase of these
organs’ sizes. At least in thymus and
spleen, 3D structures are formed that
resemble physiologic organization, in-
dicating that some cross reactivity in
organizational structures, e.g., chemo-
kine networks, exist (Traggiai et al.
[2004] and Figure 1). In contrast,
mesenteric-lymph-node organization
is less sufficient, and peripheral-
lymph-node and intestinal-lymphoid-
tissue formation does not compare
well with wild-type mice (Legrand
et al., 2006b; Macchiarini et al., 2005;
Shultz et al., 2007). This might be be-
cause of the lack of IL-7R signaling
and insufficient formation of lymphoid
tissue anlage in Il2rg/ mice. Thus,
the use of Il2rb/ instead of Il2rg/
mice might be a solution. However,
because Rag2/Il2rg/ newborn
transplantation with wild-type-mouse
bone-marrow cells or HSCs rescues
peripheral-lymph-node development
in recipients, additional defects in
cross-species interactions of, for
example, homing molecules are
probable (Coles et al. [2006] and un-
published data).
Finally, with currently available
human HSC and progenitor cells,
engraftment levels vary, probably
depending on intrinsic differences of
donor cells as well as on pretransplant
cell handling, and usually less than 10
animals can be transplanted from one
graft. For broad use of these models
as preclinical testing tools, it thus will
be important that larger, standardized,
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plants matched to human MHC com-
ponents expressed on the mouse
background will be available. This
might be achieved by HSC expansion
(use of genes with oncogenic potential
will be less of a concern compared
with clinical transplantation) and by
human embryonic stem cell (ESC) or
multipotent adult progenitor cell
(MAPC) to HSC differentiation (e.g.,
Serafini et al. [2007] and Table 2).
Current and Future Applications
Given all the discussed complexities
and limitations, what major scientific
achievements have been made, and
whatmight be reached given appropri-
ate improvements of models that
would justify the effort? No doubt, he-
matology research thus far profited
most with characterization of human
HSCs or SRCs, progenitor cells, and
leukemia stem cells (LSCs), including
identification of strategies to selec-
tively target LSCs (Jin et al., 2006). Im-
proved models are adding to this field
as greater, more durable engraftment
and lymphoid-lineage diversity is
achieved, allowing, for example, ge-
netic interference (e.g., Gimeno et al.
[2004]). Furthermore, they might be
permissive for engraftment of dis-
eased cells, e.g., myeloproliferative
syndrome cells. Reflective of above
discussed limitations, possibilities in
immunology research are just emerg-
ing, and similar impact on basic and
clinical immunology still needs to be
achieved. With recent improvements,
current models are already useful to
investigate in vivo issues such as
pathology and intervention in human-
specific lymphotropic infections, ef-
fects of hemato-lymphoid-system
antibody targeting (e.g., Legrand
et al. [2006a]), hematopoietic- and
immune-system gene therapy, and
lymphoid-system interactions with
cancer (e.g., Aspord et al. [2007]) and
cancer stem cells.
Given that ongoing efforts to
achieve a fully functional human im-
mune system in mice will work (Table
2), the breadth of possible use is going
to be tremendous, including the
following: in vivo manipulation of den-dritic, T, and B cells, generation of T
and B cell responses to autoantigens
or tumors, preclinical vaccine testing,
and evaluation of human-prion-
disease immune-system interaction.
Finally, powerful complementary
technologies are coemerging as the
capacity to replace large segments of
the mouse genome with human
sequences (e.g., T cell- and B cell-
receptor components) or the ability to
rapidly identify and reproduce human
in vivo-selected high-affinity, neutraliz-
ing antibodies to infectious agents; all
of these capabilities will enhance the
field. Thus, it is anticipated that the
use of improved, easy-to-generate,
and broadly available human-hemato-
lymphoid-system mice will gain mo-
mentum and impact on both basic
and applied preclinical human immu-
nology research over the coming
years.
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